Merck antibody drug for RSV approved by FDA

The FDA has approved Merck's Enflonsia, an antibody treatment to prevent RSV in newborns and infants, offering an alternative to Sanofi's Beyfortus, which faced supply challenges after its 2023 approval; Enflonsia demonstrated a 60% reduction in RSV disease incidence and an 84% reduction in hospitalizations in trials, and unlike Beyfortus, it can be administered regardless of an infant's weight and requires only one injection, though analysts question whether its efficacy meaningfully differs from Beyfortus.

Analysis

The Food and Drug Administration's approval of Merck & Co.'s Enflonsia (clesrovimab) marks a significant development in the pediatric respiratory syncytial virus (RSV) prevention landscape, introducing a new competitor to Sanofi and AstraZeneca's blockbuster antibody, Beyfortus. Enflonsia demonstrated a 60% reduction in RSV disease incidence and an 84% reduction in hospitalizations over five months in clinical trials, securing approval for newborns and infants. Key potential advantages for Enflonsia include its dosing convenience—a single shot applicable regardless of infant weight—which contrasts with Beyfortus, although Wall Street analysts express skepticism regarding a meaningful efficacy differentiation that could significantly impact Enflonsia's sales potential against the established Beyfortus. Sanofi has responded to Beyfortus's strong initial demand, which led to supply constraints post-its 2023 approval, by announcing accelerated shipping ahead of the upcoming RSV season. The infant RSV market remains substantial due to RSV being a leading cause of U.S. infant hospitalizations and setbacks in vaccine development for this age group, such as the FDA's pause on Moderna's infant RSV vaccine trial. While GSK, Pfizer, and Moderna have vaccines for older adults, and Pfizer’s Abrysvo offers protection to newborns via maternal vaccination, direct antibody treatments like Enflonsia and Beyfortus are crucial for immediate infant protection. Enflonsia's shipments are expected before the 2025-2026 RSV season, and upcoming CDC panel recommendations will further shape its uptake.

Key Decisions for Investors

• Investors should monitor Merck's market penetration strategy for Enflonsia, particularly its ability to leverage dosing convenience and clinical data against Sanofi's entrenched Beyfortus in the lucrative infant RSV market.
• Shareholders in Sanofi and AstraZeneca should assess the competitive impact of Enflonsia, considering Beyfortus's established demand and Sanofi's proactive supply management to maintain market leadership, while also noting the generally positive sentiment for Sanofi.
• Developments in the broader infant RSV space, including the CDC panel's recommendations for Enflonsia and any progress in pediatric RSV vaccines, warrant close attention given the significant unmet medical need and past trial setbacks for companies like Moderna, which currently carries negative sentiment in this area.